<p>在最近的三个月中，11 位分析师分享了他们对 WAVE Life Sciences（纳斯达克：WVE）的见解，表达了从看涨到看跌的各种观点。</p>
<p>在下面的表格中，您将找到他们最近评级的摘要，揭示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师提供了更深入的见解，设定了 12 个月的价格目标，显示出平均目标为 37.27 美元，最高估计为 52.00 美元，最低估计为 27.00 美元。当前平均价格目标较之前的 30.00 美元上升了 24.23%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png"/></p>
<h2>分析分析师评级：详细拆解</h2>
<p>金融专家对 WAVE Life Sciences 的看法通过最近的分析师行动进行了分析。以下摘要展示了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越市场</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>维持</td>
<td>买入</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>上调</td>
<td>超配</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>上调</td>
<td>买入</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超越市场</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越市场</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化做出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 WAVE Life Sciences 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度评估股票，评级范围从 “超越市场” 到 “表现不佳”。这些评级传达了对 WAVE Life Sciences 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师通过调整价格目标，提供 WAVE Life Sciences 未来价值的估计。比较当前和之前的目标提供了分析师期望变化的见解。</li>
</ul>
<p>为了获取 WAVE Life Sciences 市场表现的有价值见解，请考虑将这些分析师评估与关键财务指标结合使用。保持信息灵通，做出明智的决策，使用我们的评级表。</p>
<p>随时了解 WAVE Life Sciences 的分析师评级。</p>
<h2>关于 WAVE Life Sciences 的所有信息</h2>
<p>WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于开发 RNA 药物（也称为寡核苷酸），旨在转变人类健康。RNA 药物平台 PRISM 结合了多种模式、化学创新和对人类遗传学的深入洞察，以提供科学突破，治疗罕见和常见疾病。其 RNA 靶向工具包包括 RNA 编辑、反义沉默和 RNA 干扰，提供设计和可持续交付候选药物的能力，以最佳方式应对疾病生物学。其项目针对罕见和常见疾病，包括α-1 抗胰蛋白酶缺乏症、肥胖、杜氏肌营养不良和亨廷顿病。</p>
<h3>关键指标：WAVE Life Sciences 的财务健康</h3>
<p><strong>市值分析：</strong> 反映出公司规模较小，其市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
<p><strong>收入下降：</strong> 在过去的 3 个月中，WAVE Life Sciences 面临挑战，导致截至 2025 年 12 月 31 日收入增长约下降 <strong>-79.41%</strong>。这意味着公司的收入出现了减少。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平。</p>
<p><strong>净利润率：</strong> 公司的净利润率低于行业基准，表明在实现强劲盈利能力方面可能面临困难。净利润率为 <strong>-308.37%</strong>，公司可能需要解决有效成本控制方面的挑战。</p>
<p><strong>股本回报率（ROE）：</strong> WAVE Life Sciences 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-16.54%</strong>，公司可能在实现最佳财务回报方面面临障碍。</p>
<p><strong>资产回报率（ROA）：</strong> 公司的 ROA 低于行业基准，表明在有效利用资产方面可能面临困难。ROA 为 <strong>-12.09%</strong>，公司可能需要解决从其资产中产生满意回报的挑战。</p>
<p><strong>债务管理：</strong> WAVE Life Sciences 的债务与股本比率为 <strong>0.03</strong>，低于行业平均水平，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
<h2>分析师评级是如何确定的？</h2>
<p>Benzinga 跟踪 150 家分析师公司并报告他们对股票的预期。分析师通常通过预测公司未来的盈利能力，通常是未来五年，以及该公司收入来源的风险性或可预测性来得出结论。</p>
<p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或者在公司有重大更新时进行评级。</p>
<p>分析师可能通过纳入增长预期、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

生物技术临床实验 ETF - LifeSci

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

WAVE生命科学

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

<p>WAVE Life Sciences（纳斯达克代码：WVE）在过去三个月中获得了 11 位分析师的混合评级，平均 12 个月目标价为 37.27 美元，较之前的目标价上涨了 24.23%。分析师们提高或维持了他们的评级，其中 Canaccord Genuity 和 HC Wainwright & Co.等公司的评级显著上调。然而，该公司面临挑战，包括 79.41% 的收入增长下降和负净利润率。WAVE Life Sciences 专注于 RNA 药物，且其保守的债务与股本比率为 0.03，表明其对债务融资的依赖较低</p>

<p>Across the recent three months, 11 analysts have shared their insights on WAVE Life Sciences (NASDAQ: WVE), expressing a variety of opinions spanning from bullish to bearish.</p>
<div class="lb-trans"><p>在最近的三个月中，11 位分析师分享了他们对 WAVE Life Sciences（纳斯达克：WVE）的见解，表达了从看涨到看跌的各种观点。</p>
</div><p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<div class="lb-trans"><p>在下面的表格中，您将找到他们最近评级的摘要，揭示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.27, along with a high estimate of $52.00 and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 24.23% from the previous average price target of $30.00.</p>
<div class="lb-trans"><p>分析师提供了更深入的见解，设定了 12 个月的价格目标，显示出平均目标为 37.27 美元，最高估计为 52.00 美元，最低估计为 27.00 美元。当前平均价格目标较之前的 30.00 美元上升了 24.23%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773165696_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1773165696_0.png"/></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<div class="lb-trans"><h2>分析分析师评级：详细拆解</h2>
</div><p>The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>金融专家对 WAVE Life Sciences 的看法通过最近的分析师行动进行了分析。以下摘要展示了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>$52.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越市场</td>
<td>$35.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>维持</td>
<td>买入</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steve Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>上调</td>
<td>超配</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright  Co.</td>
<td>上调</td>
<td>买入</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Cheng Li</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超越市场</td>
<td>$32.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$37.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>上调</td>
<td>超越市场</td>
<td>$33.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WAVE Life Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for WAVE Life Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化做出反应，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 WAVE Life Sciences 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度评估股票，评级范围从 “超越市场” 到 “表现不佳”。这些评级传达了对 WAVE Life Sciences 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师通过调整价格目标，提供 WAVE Life Sciences 未来价值的估计。比较当前和之前的目标提供了分析师期望变化的见解。</li>
</ul>
</div><p>For valuable insights into WAVE Life Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获取 WAVE Life Sciences 市场表现的有价值见解，请考虑将这些分析师评估与关键财务指标结合使用。保持信息灵通，做出明智的决策，使用我们的评级表。</p>
</div><p>Stay up to date on WAVE Life Sciences analyst ratings.</p>
<div class="lb-trans"><p>随时了解 WAVE Life Sciences 的分析师评级。</p>
</div><h2>All You Need to Know About WAVE Life Sciences</h2>
<div class="lb-trans"><h2>关于 WAVE Life Sciences 的所有信息</h2>
</div><p>WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.</p>
<div class="lb-trans"><p>WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于开发 RNA 药物（也称为寡核苷酸），旨在转变人类健康。RNA 药物平台 PRISM 结合了多种模式、化学创新和对人类遗传学的深入洞察，以提供科学突破，治疗罕见和常见疾病。其 RNA 靶向工具包包括 RNA 编辑、反义沉默和 RNA 干扰，提供设计和可持续交付候选药物的能力，以最佳方式应对疾病生物学。其项目针对罕见和常见疾病，包括α-1 抗胰蛋白酶缺乏症、肥胖、杜氏肌营养不良和亨廷顿病。</p>
</div><h3>Key Indicators: WAVE Life Sciences's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：WAVE Life Sciences 的财务健康</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出公司规模较小，其市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
</div><p><strong>Decline in Revenue:</strong> Over the 3M period, WAVE Life Sciences faced challenges, resulting in a decline of approximately <strong>-79.41%</strong> in revenue growth as of 31 December, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入下降：</strong> 在过去的 3 个月中，WAVE Life Sciences 面临挑战，导致截至 2025 年 12 月 31 日收入增长约下降 <strong>-79.41%</strong>。这意味着公司的收入出现了减少。与医疗保健行业的其他公司相比，该公司的增长率低于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-308.37%,</strong> the company may need to address challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 公司的净利润率低于行业基准，表明在实现强劲盈利能力方面可能面临困难。净利润率为 <strong>-308.37%</strong>，公司可能需要解决有效成本控制方面的挑战。</p>
</div><p><strong>Return on Equity (ROE):</strong> WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-16.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> WAVE Life Sciences 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-16.54%</strong>，公司可能在实现最佳财务回报方面面临障碍。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-12.09%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 公司的 ROA 低于行业基准，表明在有效利用资产方面可能面临困难。ROA 为 <strong>-12.09%</strong>，公司可能需要解决从其资产中产生满意回报的挑战。</p>
</div><p><strong>Debt Management:</strong> WAVE Life Sciences's debt-to-equity ratio is below the industry average at <strong>0.03</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> WAVE Life Sciences 的债务与股本比率为 <strong>0.03</strong>，低于行业平均水平，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析师评级是如何确定的？</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟踪 150 家分析师公司并报告他们对股票的预期。分析师通常通过预测公司未来的盈利能力，通常是未来五年，以及该公司收入来源的风险性或可预测性来得出结论。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析师参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布他们对股票的评级。分析师通常每季度对每只股票进行一次评级，或者在公司有重大更新时进行评级。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析师可能通过纳入增长预期、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

benzinga_article

WAVE 生命科学股票：深入探讨分析师观点（11 个评级）